Jump to content

Christine Allen

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cassiopeia (talk | contribs) at 12:15, 2 August 2018 (authority control). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This sandbox is in the article namespace. Either move this page into your userspace, or remove the {{User sandbox}} template. Christine Allen is a Canadian Professor and GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery, University of Toronto in the Leslie Dan Faculty of Pharmacy. She is the co-Founder of Nanovista[1], which is a company focused on imaging of tumors. [1] Currently, she serves as Associate Editor of Molecular Pharmaceutics.[2] She received her PhD in Chemistry at McGill University and completed a post doc in the Department of Advanced Therapeutics at the BC Cancer Agency. Prior to joining University of Toronto in 2002 she worked as a scientist and assistant directors of materials research at Celator Pharmaceuticals.[2] Dr. Allen's research is focused in the field of drug delivery. In particular, micelles and gold nanoparticles for cancer therapy.[3][4] She has developed several block-co-polymers, particularly those with PEG, for delivery of cancer chemotherapeutics.[3] For cancer imaging as well as theranostic applications, the Allen lab has developed several gold nanoparticle carriers.[4] Her platforms apply concepts in drug delivery, targeted drug delivery, as well as controlled release. She has numerous patents, and over 90 publications.[2] Also, she has received many awards including:

  • 2014 Gattefossé Canada/CSPS Award in Lipid-Based Drug Delivery[5]
  • 2011 CRS/Elsevier Journal of Controlled Release Jorge Heller Award for Outstanding Paper[6]
  • Innovation Award - Ontario Research and Commercialization Program, 2008
  • Career Award - Canadian Institutes of Health Research (CIHR)/Rx&D, 2004-2009
  • New Investigator Research Award - Association of Faculties of Pharmacy of Canada (AFPC)/AstraZeneca, 2006
  • Early Career Award - Canadian Society for Pharmaceuticals Sciences (CSPS)/GlaxoSmithKline, 2006

References

  1. ^ "Christine Allen Women enabling science to reach the people who need it". Johnson & Johnson Innovation Labs. Retrieved 30 July 2018.
  2. ^ a b c "Christine Allen". Controlled Release Society. Retrieved 30 July 2018.
  3. ^ a b Houdaihed, L; Evans, JC; Allen, C (2017). "Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic". Mol Pharm. 14 (8): 2503-2517. PMID 28481116. Retrieved 1 August 2018.
  4. ^ a b Her, S; Jaffray, DA; Allen, C (2017). "Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements". Adv Drug Deliv Rev. 109: 84-101. PMID 26712711. Retrieved 1 August 2018.
  5. ^ Dou, Yannan; Zheng, Jinzi; Foltz, Warren; Weersink, Robert; Chaudary, Naz; Jaffray, David; Allen, Christine (25 September 2011). "Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice". Journal of Controlled Release. 178 (23): 69-78. PMID 24440663. Retrieved 31 July 2018.
  6. ^ Dunn, Michael; Zheng, Jinzi; Rosenblat, Joshua; Jaffray, David; Allen, Christine (25 September 2011). "APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes". Journal of Controlled Release. 154 (3): 298-305. PMID 21640146. Retrieved 31 July 2018.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Christine_Allen&oldid=853098390"